Cassava Sciences Inc vs Honest Company Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Honest Company Inc trades at $5.08 (market cap $558.95M). The key difference: Honest Company Inc is far larger — about 11.7× Cassava Sciences Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | HNST | |
|---|---|---|
Market Cap | $47.75M | $558.95M |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $5.46 |
52-Week Low | $0.87 | $2.10 |
Enterprise Value | -$34.93M | $462.56M |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
HNST trades at $5.065, down 3.15% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q2 2026 results with an earnings beat but declining revenue due to strategic exits. Despite negative net income margins and ROE, cash flow improved significantly in 2025 with $14.15M net cash flow. Analyst consensus shows 30% buy ratings amid ongoing profitability challenges.
The outlook remains cautious as strategic exits pressure revenue while cost improvements support margins. Investment opportunity exists if profitability targets are met, but risks include persistent net losses and competitive pressures in personal care markets. The stock's elevated P/E ratio of 48.83 requires careful valuation assessment.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →